sameAs
Future prospects in the treatment of erectile dysfunction: focus on avanafil.Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers.Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction.A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction.Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction.Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction.Looking to the future for erectile dysfunction therapies.Novel phosphodiesterase type 5 modulators: a patent survey (2008 - 2010).Avanafil for the treatment of erectile dysfunction.Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial.A phase II, single-blind, randomized, crossover evaluation of the safety and efficacy of avanafil using visual sexual stimulation in patients with mild to moderate erectile dysfunctionDaily Avanafil for Erectile DysfunctionNovel phosphodiesterase-5 (PDE5) inhibitors in the alleviation of erectile dysfunction due to diabetes and ageing-induced oxidative stress
P921
Q34029414-546ACB83-29DA-4F6A-B5A9-3EF1C56D7855Q34621613-B9B261BA-DDB6-4FC8-B6E4-DD9BD9F013CDQ34624315-482104D6-9B41-4EE3-B872-BD825E661758Q34635135-046E68BD-50E0-4F73-A2BA-3E5859F4B5D4Q34639327-F558E65A-DB9F-4076-A196-39FCEF79CF92Q35183603-083C9904-D89E-4F7C-89E7-D5AA8B8695FCQ37058008-DFB37E28-84FC-427A-BE13-F55ED1B8684AQ37929740-8EFB9DB0-CA4C-4BA9-B9C7-CCE38FDCDEB4Q37989951-9F4088CB-F1E6-4A9E-B1AA-1DB0F1481F76Q38023638-B902ACD8-2BF0-46EF-814A-B911D905F806Q38464139-95868A39-22E5-424A-B96F-129B7DAE3EF9Q84566769-08771E62-95D5-4842-99E8-6EC986C0C3E9Q93422357-EF9F8268-3E76-472B-9E91-755B14A80878Q94700470-F641BE39-B2F7-4E59-B8B6-6975BCCAD74B
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Avanafil
@de
Avanafil
@it
Avanafil
@nb
Avanafil
@nl
Avanafil
@ro
Avanafil
@sh
Avanafil
@sv
Avanafil
@vi
Awanafil
@pl
avanafil
@en
type
label
Avanafil
@de
Avanafil
@it
Avanafil
@nb
Avanafil
@nl
Avanafil
@ro
Avanafil
@sh
Avanafil
@sv
Avanafil
@vi
Awanafil
@pl
avanafil
@en
altLabel
(S)-4-(3-Chloro-4-methoxybenzy ...... methyl-5-pyrimidinecarboxamide
@en
Avanafil
@en
Avanafila
@pt
C23H26ClN7O3
@fr
Spedra®
@en
Stendra®
@en
TA-1790
@en
prefLabel
Avanafil
@de
Avanafil
@it
Avanafil
@nb
Avanafil
@nl
Avanafil
@ro
Avanafil
@sh
Avanafil
@sv
Avanafil
@vi
Awanafil
@pl
avanafil
@en
P592
P6366
P646
P661
P662
P665
P6694
P683
P117
P1579
P2017
COC1=C(C=C(C=C1)CNC2=NC(=NC=C2C(=O)NCC3=NC=CC=N3)N4CCC[C@H]4CO)Cl
P2067
483.178565
P2115
N0000189941